Institutul National De Neurologie Si Boli Neurovasculare Bucuresti
- Address
- Soseaua Berceni 10-12 Sector 4, 041902 Bucharest, Romania
Cardiovascular Diseases
Clinical research at Institutul National De Neurologie Si Boli Neurovasculare Bucuresti includes studies in cardiovascular diseases focused on acute ischemic stroke and high-risk transient ischemic attack. These trials are designed to assess whether new treatment approaches can help lower the chance of another stroke and improve prevention after a recent cerebrovascular event.
- Acute ischemic stroke
- High-risk transient ischemic attack
- Testing a therapy aimed at reducing recurrent ischemic events
This area reflects a strong interest in improving outcomes for patients at risk of serious vascular complications through more effective stroke prevention strategies.
Nervous System Diseases
The site also conducts research in nervous system diseases, with a focus on chronic inflammatory demyelinating polyneuropathy (CIDP). The trial activity in this field is aimed at evaluating treatment effectiveness and supporting better functional recovery for adults living with this rare neurological condition.
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Assessing a treatment option for improved functional ability
- Comparing approaches to better manage a chronic neurological disorder
Work in Neurologie I highlights the role of the Bucharest center in advancing care for complex neurological disorders through clinically focused research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Argenx1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institutul National De Neurologie Si Boli Neurovasculare Bucuresti
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.